Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue SUPPL.1, 2014, Pages 1-9

  Sievert, William ^a   Razavi, Homie ^f   Estes, Chris ^f   Thompson, Alexander J ^b   Zekry, Amany ^d   Roberts, Stuart K ^c   Dore, Gregory J ^e  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Center for Disease Analysis   (United States)

Author keywords

Australia; Cirrhosis; Diagnosis; Directly acting antivirals; Hepatitis C; Hepatocellular carcinoma; Treatment

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; ADOLESCENT; CARCINOMA, HEPATOCELLULAR; CHILD; COMPLICATION; COST OF ILLNESS; ECONOMICS; EPIDEMIOLOGY; HEPATITIS C, CHRONIC; INFANT; LIVER NEOPLASMS; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; AUSTRALIA; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFANT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84904737571     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12677     Document Type: Article

References (38)

1. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 2006; 13: 34-41.
2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431.
3. The Kirby Institute for Infection and Immunity in Society. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Reports 1997-2013. 2014. Available at: http://kirby.unsw.edu.au/surveillance/Annual-Surveillance-Reports (accessed 11 July 2014).
4. Razali K, Thein HH, Bell J etal. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91: 228-235.
5. Gidding HF, Law MG, Amin J etal. Hepatitis C treatment outcomes in Australian clinics. Med. J. Aust. 2012; 196: 633-637.
6. Gidding HF, Topp L, Middleton M etal. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006. J. Gastroenterol. Hepatol. 2009; 24: 1648-1654.
7. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
8. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
9. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
10. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
11. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
12. Dore GJ. The changing therapeutic landscape for hepatitis C. Med. J. Aust. 2012; 196: 629-632.
13. Ferenci P, Bernstein D, Lalezari J etal. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 2014; 370: 1983-1992.
14. Sulkowski MS, Gardiner DF, Rodriguez-Torres M etal. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370: 211-221.
15. Bruggmann P, Berg T, Ovrehus AL etal. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J. Viral Hepat. 2014; 21 (Suppl. 1): 5-33.
16. Razavi H, Waked I, Sarrazin C etal. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J. Viral Hepat. 2014; 21 (Suppl. 1): 34-59.
17. Wedemeyer H, Duberg AS, Buti M etal. Strategies to manage hepatitis C virus (HCV) disease burden. J. Viral Hepat. 2014; 21 (Suppl. 1): 60-89.
18. United Nations. Department of Economic and Social Affairs. Population Division. World Population Prospects: The 2010 Revision, Volume I: Comprehensive Tables. ST/ESA/SER.A/313.2011. Available at: http://esa.un.org/wpp/ (accessed 11 July 2014).
19. Australian Government Department of Health and Ageing. National Notifiable Diseases Surveilllance System. Notifications of a selected disease by age group, sex and year: Hepatitis C (newly acquired) and Hepatitis C (unspecified): 1995-2013. 2014. Available at: http://www9.health.gov.au/cda/source/cda-index.cfm (accessed 11 July 2014).
20. Victorian Infectious Diseases Reference Laboratory. Hepatitis Virus Characterisation. 2013. Available at: http://www.vidrl.org.au/laboratories/hepatitis-reference/hepatitis-virus-characterisation/ (accessed 11 July 2014).
21. Razali K, Amin J, Dore GJ, Law MG, HCV Projections Working Group. Modelling and calibration of the hepatitis C epidemic in Australia. Stat. Methods Med. Res. 2009; 18: 253-270.
22. Australia & New Zealand Organ Donation Registry. Annual Reports (1997-2012). 2014. Available at: http://www.anzdata.org.au/anzod/v1/reports.html (accessed 11 July 2014).
23. Australia Dept. of Health and Aging. Third National Hepatitis C Strategy 2010-2013. Canberra: Commonwealth of Australia, 2010.
24. University of California Berkeley, Max Planck Institute for Demographic Research. Human Mortality Database. Wilmoth JR, Shkolnikov V, editors. 2013. Berkeley, USA; Rostock, Germany, Available at: http://www.mortality.org/ (accessed 11 July 2014).
25. Engstrom A, Adamsson C, Allebeck P, Rydberg U. Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973-1984. Int. J. Addict. 1991; 26: 91-106.
26. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997; 92: 419-427.
27. Hickman M, Carnwath Z, Madden P etal. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J. Urban Health 2003; 80: 274-287.
28. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299-1308.
29. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F. Mortality of intravenous drug users in Rome: a cohort study. Am. J. Public Health 1991; 81: 1307-1310.
30. Bjornaas MA, Bekken AS, Ojlert A etal. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry 2008; 8: 8.
31. Kamper-Jorgensen M, Ahlgren M, Rostgaard K etal. Survival after blood transfusion. Transfusion 2008; 48: 2577-2584.
32. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J. Manag. Care Pharm. 2011; 17: 531-546.
33. Reserve Bank of Australia. G2 Consumer Price Inflation-Expenditure Groups. 2014. Sydney, Reserve Bank of Australia. Available at: http://www.rba.gov.au/statistics/index.html (accessed 11 July 2014).
34. Gidding HF, Amin J, Dore GJ, Ward K, Law MG. Hospital-related morbidity in people notified with hepatitis C: a population-based record linkage study in New South Wales, Australia. J. Hepatol. 2010; 53: 43-49.
35. Gidding HF, Dore GJ, Amin J, Law MG. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health 2011; 11: 52. doi: 10.1186/1471-2458-11-52.
36. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin. Gastroenterol. Hepatol. 2011; 9: 509-516.
37. van der Meer AJ, Veldt BJ, Feld JJ etal. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
38. van der Meer AJ, Veldt BJ, Feld JJ etal. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. J. Viral Hepat. 2013; 21: 568-577.